Results 211 to 220 of about 236,724 (287)

MRI-Based Radiomics Model for Predicting Eligibility for Conservative Management of Endometrial Cancer. [PDF]

Cancer Med
Ding S, Meng H, Cui X, Yang Y, Xing L, Zuo Z, Liu C, Xue L, Yin X.   +8 more
europepmc   +1 more source

Evidence That the Protein Phosphatase Activity of PTEN Contributes to Embryonic Development and Tumor Suppression

Cancer Science, EarlyView.
Mice expressing only mutant PTEN Y138L, a protein which shows normal suppression of cellular AKT yet lacks protein phosphatase activity, die in utero, and heterozygous mice display a range of tumors. This indicates both the lipid and protein phosphatase activities of PTEN work together for normal tumor suppression and embryonic development.
Priyanka Tibarewal, Laura Spinelli, Nisha Kriplani, Helen Wise, Nadege Poncet, Giulia Marzano, Karen E. Anderson, Katarzyna M. Grzes, Zofia Varyova, Mahreen Adil, C. Peter Downes, Phillip T. Hawkins, Len R. Stephens, Kate G. Storey, Doreen A. Cantrell, Bart Vanhaesebroeck, Nicholas R. Leslie   +16 more
wiley   +1 more source

A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer. [PDF]

Clin Cancer Res
Santin AD, Roque DM, Siegel ER, Ettorre VM, Greenman M, McNamara B, Papatla K, Kailasam A, Buza N, Clark M, Hui P, Dottino P, Ratner E, Bellone S.   +13 more
europepmc   +1 more source

TRIM59 Drives Bladder Cancer Progression Through E3 Ligase‐Dependent K48‐Linked Degradation of PTRF

Cancer Science, EarlyView.
Schematic model of TRIM59‐driven BLCA progression through K48‐linked ubiquitination and proteasomal degradation of PTRF, leading to AKT activation and c‐Myc upregulation. ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood ...
Junlin Gan, Xuesong Bai, Aijie Zhang, Fei Lin, Hang Tong, Tinghao Li, Ning Xu, Xinyuan Li, Zhou Yu, Hubin Yin   +9 more
wiley   +1 more source

Post-diagnosis physical activity in relation to mortality among gynecological cancer survivors. [PDF]

Cancer Causes Control
Hamann A, Benker P, Leitzmann MF, Stein MJ.   +3 more
europepmc   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Integration of Artificial Intelligence in Endometrial Cancer Management. [PDF]

Cureus
Safini F, Abbaoui S, Semghouli S, Amaoui B.   +3 more
europepmc   +1 more source

EPHX2 Loss Promotes CRC Migration via EET‐Dependent Chemokine Elevation and Mitochondrial Defect

Cancer Science, EarlyView.
Loss of EPHX2 promotes EET accumulation, which in turn enhances CXCL and ROS production, thereby promoting the migratory and invasive abilities of CRC cells. ABSTRACT Epoxide hydrolase 2 (EPHX2) is a key enzyme in fatty acid metabolism that metabolizes epoxyeicosatrienoic acids (EETs), lipid mediators involved in inflammation, angiogenesis, and ...
Jianjun Zhu, Jingjia Chang, Zhiyong Li, Jin Wu, Pengfei Yu, Jingjing Zheng, Li Li, Jia Tao, Hao Wu, Yintao Li, Ming Liu   +10 more
wiley   +1 more source

MicroRNA-204 and microRNA-652-3p as promising biomarkers for endometrial cancer diagnosis and prognosis. [PDF]

Rev Assoc Med Bras (1992)
Minareci Y, Sözen H, Toyran A, Kucukgergin C, Aydın F, Bingul İ, Gunver MG, Akkoyunlu SZ, Topuz S, Salihoglu MY.   +9 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source